Boston Scientific Corporation (NYSE:BSX) reported upbeat earnings for the fourth quarter on Wednesday.
The company posted fourth-quarter 2025 revenues of $5.29 billion on Wednesday, almost in line with the consensus estimate of $5.28 billion, beating the management guidance of $5.22 billion-$5.31 billion. The medical technology giant reported adjusted earnings of 80 cents, beating the consensus of 78 cents and the management guidance of 77-79 cents.
Boston Scientific forecasts net sales growth of approximately 10.5%-11.5% in 2026 on a reported basis, and 10%-11% organically. The sales are expected to be between $22.18 billion-$22.38 billion, versus the consensus of $22.37 billion.
The company estimates adjusted earnings of $3.43 to $3.49 compared to the consensus of $3.47 per share.
Boston Scientific shares gained 0.6% to $75.92 in pre-market trading.
These analysts made changes to their price targets on Boston Scientific following earnings announcement.
- Needham analyst Mike Matson maintained Boston Scientific with a Buy and lowered the price target from $121 to $97.
- Truist Securities analyst Richard Newitter maintained the stock with a Buy and lowered the price target from $120 to $95.
- Mizuho analyst Anthony Petrone maintained Boston Scientific with an Outperform rating and lowered the price target from $140 to $115.
- Baird analyst David Rescott maintained Boston Scientific with an Outperform rating and cut the price target from $118 to $101.
- Stifel analyst Rick Wise maintained the stock with a Buy and lowered the price target from $125 to $110.
Considering buying BSX stock? Here’s what analysts think:
Photo via Shutterstock